Abstracts tagged "Pharmacists"

Abstract Number: 124 • 2020 Pediatric Rheumatology Symposium
Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic
Shannon Rotolo ¹, Grace Cameron², Cuoghi Edens ¹ and Constentina Talevski ³, ¹UCM, Chicago, ²UCM, Oak Lawn, ³Univeristy of Chicago Medicine, Lockport
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease in which the body produces pathogenic autoantibodies that cause inflammation resulting in multi-organ damage. A SLE…
Abstract Number: 1247 • 2018 ACR/ARHP Annual Meeting
Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
Irvin Huang¹, Jean Liew², Meredith Barnes³, Silu Zuo⁴, Carol Crawford⁴ and Alison Bays⁵, ¹Internal Medicine, Boise VAMC, Boise, ID, ²Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ³Medicine, University of Washington, Seattle, WA, ⁴Harborview Medical Center, Seattle, WA, ⁵Division of Rheumatology, University of Washington, Seattle, CA
Background/Purpose: The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines.…
Abstract Number: 1046 • 2017 ACR/ARHP Annual Meeting
Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Wendy Ramey¹, Kristine M. Lohr², Matt Zeltner¹, Haley Herrell Postonl¹, Andrew Johannemann¹, Aric D. Schadler¹ and Aleksander Lenert³, ¹University of Kentucky, Lexington, KY, ²Rheumatology, University of Kentucky, Lexington, KY, ³Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY
Background/Purpose: Treatment with biological DMARDs (bDMARD) and targeted synthetic DMARDs (tsDMARD) has led to improved outcomes for chronic rheumatic diseases. Current treat-to-target (T2T) strategy relies…
Abstract Number: 1492 • 2015 ACR/ARHP Annual Meeting
Implementation in Clinical Practice of a Medication Assessment Tool Specific for Rheumatoid Arthritis, Rhmat
Louise Grech^1,2, Anthony Serracino Inglott¹, Victor Ferrito¹ and Lilian M. Azzopardi¹, ¹Department of Pharmacy, University of Malta, Msida, Malta, ²Clinical Pharmacy Practice Unit, Department of Pharmacy, Mater Dei Hospital, Msida, Malta
Background/Purpose: The RhMAT is a medication assessment tool developed to specifically analyse pharmacotherapy adherence to evidence based medicine and guidelines on the management of rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].